Carregant...
How should we treat vascular and fibrotic lung disease in scleroderma?
Recent randomized trials suggest that evidence-based algorithms for systemic sclerosis can be developed to identify patients at risk for lung disease, follow lung disease progression, and modify disease with therapies of proven benefit. Recognition of disease subsets allows physicians to integrate p...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Medicine Reports Ltd
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2948303/ https://ncbi.nlm.nih.gov/pubmed/20948723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3410/M1-57 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|